摘要
目的:评价CA242、CA19蛳9和CEA在大肠癌诊断中的意义。方法:采用酶联免疫和放射免疫法分别检测40例健康人、42例炎性肠病患者和74例大肠癌患者CA242、CA19蛳9和CEA的含量。结果:大肠癌患者CA242、CA19蛳9和CEA抗原表达均分别高于健康人和炎性肠病患者,具有显著性差异。其中CA242特异性最好,为89.42%。在大肠癌患者中CA19蛳9检出率最高,为83.78%。CA242、CA19蛳9分别在结肠癌和直肠癌中的表达水平不同,其差异具有显著性意义。结论:血清CA242、CA19蛳9和CEA的联合检测有利于大肠癌的早期诊断,也可作为大肠癌治疗药物疗效评价的重要依据。
objective: To evaluate the clinical significance for the measurement of CA242/CA19-9 and CEA level in diagnosing large intestine carcinoma. Methods: CA242,CA19-9 and CEA levels in the serum of 40 cases of healthy people, 42 cases of inflammatory intestine and 74 cases of large intestine carcinoma were measured by enzyme linked immunosorbent assay and radioimmunoassay method, respectively. Results: The results showed that CA242,CA19-9 and CEA levels in patients with large intestine carcinoma were all higher than the levels in healthy people and patients with inflammatory intestine, respectively, and the differences between patients with large intestine carcinoma and healthy people and patients with inflammatory intestine were of obvious significance, and CA242 in serum of 89.42 % of patients with large intestine carcinoma were positive and it's specificity was best among the three groups. In serum of patients with large intestine carcinoma, the positive ratio(83.78 %) of CA19-9 was the highest. The levels of expression of CA242 and CA19-9 in carcinoma of colon and rectal carcinoma were with significant differences. Conclusion: The results of measurement of CA242, CA19-9 and CEA contributed to early diagnosis of large intestine carcinoma and could be regarded as important basis of evaluation of the drugs to treat large intestine carcinoma.
出处
《肿瘤研究与临床》
CAS
2004年第4期227-229,共3页
Cancer Research and Clinic
